Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
What's New: August 2026 Update TRIUMPH-2 CONFIRMED (July 23, 2026): Obesity + type 2 diabetes trial, 1,152 patients up to 20.8% weight loss (12mg) and up to -1.6 percentage points HbA1c reduction at 80 weeks TRIUMPH-3 CONFIRMED (July 23, 2026): Obesity + established cardiovascular disease trial, 1,949 patients up to 22.6% weight loss (12mg) at 80 weeks, plus significant improvements in triglycerides, blood pressure, and inflammatory markers All four core TRIUMPH registrational trials are now complete TRIUMPH-4, TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3 have all reported positive topline results TRIUMPH-1 reminder: 45.3% of patients on 12mg lost 30% of body weight, and a 104-week extension in patients with BMI 35 reached up to 30.3% average weight loss surgical-level outcomes that remain the strongest efficacy data in the program Filing type confirmed: BLA, not NDA Eli Lilly will submit a Biologics License Application (retatrutide is regulated as a biologic), now expected Q1 2027 (shifted from the previously estimated Q4 2026) Lilly's own statement: "With the positive results from TRIUMPH-2 and TRIUMPH-3, we now have the clinical data package to support global submissions for retatrutide as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea" TRIUMPH-Outcomes (cardiovascular and kidney outcomes, ~10,000 patients) remains separate and ongoing not expected until 20282029, and not required for initial approval Current Status: Where Things Stand Retatrutide is an investigational medication developed by Eli Lilly
Yet, rather surprisingly, only Novo Nordisk and Eli Lilly have marketed GLP-1 drugs for weight loss
Omega-3 fatty acids, present in fish oil supplements, have been associated with positive effects on various symptoms of autism, including hyperactivity, social withdrawal, cognition, and social skills [6]
This sustained-release pattern from weekly injections allows smaller total doses to produce comparable or stronger therapeutic effects than daily oral tablets, which is why injections often outperform oral formulations in clinical trials measuring weight loss and glucose control
REAL RESULTS: Lemme is expertly formulated with clinically-studied ingredients that leave you feeling your best
In clinical trials, people taking the highest dose lost an average of 28.7% of their body weight at 68 weeks
